共 50 条
Late-effects of Chemoradiotherapy on Growth and Puberty in Survivors of Childhood Acute Lymphoblastic Leukemia
被引:0
|作者:
Eltan, Sevgi Bilgic
[1
]
Akcay, Arzu
[2
]
Bayramoglu, Elvan
[3
]
Eltan, Mehmet
[4
]
Akcay, Teoman
[5
]
Salcioglu, Zafer
[5
]
Aydogan, Gonul
[6
]
机构:
[1] Marmara Univ, Dept Pediat Allergy & Immunol, Fac Med, Istanbul, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Altunizade Hosp, Fac Med, Clin Pediat Hematol & Oncol, Istanbul, Turkiye
[3] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pediat Endocrinol, Istanbul, Turkiye
[4] Univ Hlth Sci Turkiye, Istanbul Sancaktepe Sehit Prof Dr Ilhan Varank Tra, Clin Pediat Endocrinol, I?stanbul, Turkiye
[5] Uskudar Univ, Sisli Mem Hosp, Clin Pediat, Fac Med, I?stanbul, Turkiye
[6] Univ Hlth Sci Turkiye, Istanbul Kanuni Sultan Suleyman Training & Res Hos, Clin Pediat Hematol & Oncol, I?stanbul, Turkiye
来源:
TRENDS IN PEDIATRICS
|
2022年
/
3卷
/
04期
关键词:
Acute lymphoblastic leukemia;
growth;
late effects;
puberty;
obesity;
BODY-MASS-INDEX;
CRANIAL IRRADIATION;
BINDING PROTEIN-3;
REFERENCE VALUES;
ADULT SURVIVORS;
SHORT STATURE;
CHILDREN;
HEIGHT;
CHEMOTHERAPY;
PATTERNS;
D O I:
10.4274/TP.2022.43043
中图分类号:
R72 [儿科学];
学科分类号:
100202 ;
摘要:
Objective: The survival rate of childhood leukemia has reached 80% with evolving treatment modalities over the last 30 years, which is followed by an increased incidence of treatment -related long-term side effects. This study, it was aimed to evaluate the endocrine late effects of chemoradiotherapy in childhood acute lymphoblastic leukemia (ALL). Methods: Forty-eight patients with ALL treated at the University of Health Sciences T & uuml;rkiye, & Idot;stanbul Kanuni Sultan S & uuml;leyman Training and Research Hospital, Clinic of Pediatric Hematology and Oncology between 1997 and 2007 with at least 5 -year follow-up after the chemotherapy, were included. Results: Endocrine side effects were detected in 48% (n=23) of the cases. The most common endocrine side effect was short stature in the group treated with cranial radiotherapy (CRT), and obesity in the group that did not receive CRT. The median height standard deviation score (SDS) of the subjects who reached the final height (FH) was significantly lower [-1.44 (-2.1)-(-0.53)] compared with the median height SDS of the subjects who did not reach the FH [-0.24 (-1.23)-(0.6)]. There was a positive correlation between height SDS and IGF1 SDS, IGFBP3 SDS, body mass index SDS, and advanced bone age in subjects who did not reach FH (r=0.511, p=0.018, r=0.530, p=0.014, r=0.499, p=0.021, r=0.599, p=0.08, respectively). Precocious puberty was found in one patient who received CRT, and hypergonadotropic hypogonadism was found in one patient who did not receive CRT. Twenty-three percent of the group received CRT and 35% of the group who did not receive CRT had overweight/obesity. Central hypothyroidism was detected in one case and subclinical hypothyroidism was detected in two cases. Conclusion: Long-term endocrine side effects were observed in approximately half of the cases with childhood ALL. Children treated with chemoradiotherapy should have endocrine evaluation and from the until the is
引用
收藏
页码:163 / 169
页数:7
相关论文